Cargando…

CD133 antigen expression in ovarian cancer

BACKGROUND: Much attention has been recently focused on the role of cancer stem cells (CSCs) in the initiation and progression of solid malignancies. Since CSCs are able to proliferate and self-renew extensively, thus sustaining tumor growth, the identification of CSCs through their antigenic profil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrandina, Gabriella, Martinelli, Enrica, Petrillo, Marco, Prisco, Maria Grazia, Zannoni, Gianfranco, Sioletic, Stefano, Scambia, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224735/ https://www.ncbi.nlm.nih.gov/pubmed/19583859 http://dx.doi.org/10.1186/1471-2407-9-221

Ejemplares similares

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
por: Ferrandina, G, et al.
Publicado: (2008)

Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer
por: Petrillo, Marco, et al.
Publicado: (2015)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients
por: Coco, Claudio, et al.
Publicado: (2012)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo?
por: Baranello, Cinzia, et al.
Publicado: (2012)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2015)

The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma
por: Stefano, Sioletic, et al.
Publicado: (2019)

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
por: Ferrandina, G, et al.
Publicado: (2005)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2016)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
por: Legge, Francesco, et al.
Publicado: (2011)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
por: Mantegna, Giovanna, et al.
Publicado: (2013)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Expression and localisation of osteopontin and prominin-1 (CD133) in patients with endometriosis
por: D’AMICO, FABIO, et al.
Publicado: (2013)

The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer
por: Leonardi, Simona, et al.
Publicado: (2017)

Quantum dots affect expression of CD133 surface antigen in melanoma cells
por: Steponkiene, Simona, et al.
Publicado: (2011)

CD133 Act as an Essential Marker in Ovarian Carcinogenesis
por: Ikram, Dzul, et al.
Publicado: (2021)

The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
por: Min, Kyung-Jin, et al.
Publicado: (2012)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche
por: Roy, Lynn, et al.
Publicado: (2018)

Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
por: Ercoli, A, et al.
Publicado: (1999)

Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control
por: Petrillo, Marco, et al.
Publicado: (2016)

Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis
por: Ciccarone, Francesca, et al.
Publicado: (2022)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

CD133 expression in different stages of gastric adenocarcinoma
por: Boegl, M, et al.
Publicado: (2009)

Expression of CD 133 in Invasive Ductal Carcinoma of Breast
por: Utnal, Preeti Ashok, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ld2qc86f80t1p9r2rrfm3b45e3